Showing results (171-180 of 188) with videos related to
Sort By:
Pageof 19
Science Advances|December 1, 2021
Biomaterials direct functional B cell response in a material-specific mannerErika M Moore, David R Maestas, Chris C Cherry, et al.Social Cognitive and Affective Neuroscience|September 22, 2012
Branding and a child's brain: an fMRI study of neural responses to logosAmanda S Bruce, Jared M Bruce, William R Black, et al.Investigational New Drugs|August 22, 2014
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinomaNizar M Tannir, Andres Forero-Torres, Radhakrishnan Ramchandren, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2019
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 TherapyJonathan E Rosenberg, Peter H O'Donnell, Arjun V Balar, et al.MMWR. Morbidity and Mortality Weekly Report|July 10, 2015
Community Knowledge, Attitudes, and Practices Regarding Ebola Virus Disease - Five Counties, Liberia, September-October, 2014Miwako Kobayashi, Karlyn D Beer, Adam Bjork, et al.Cancer|January 10, 2019
A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinomaSumanta K Pal, Andres Forero-Torres, John A Thompson, et al.Hawaii Medical Journal|June 16, 2006
Evaluation of secondhand smoking characteristics in asthmatic children presenting to four emergency departments on O'ahu, Hawai'iRodney B Boychuk, Brunhild M Halm, Francisco Garcia, et al.Bioorganic & Medicinal Chemistry Letters|March 14, 2000
The discovery and synthesis of highly potent, A2a receptor agonistsS E Keeling, F D Albinson, B E Ayres, et al.Stem Cells (Dayton, Ohio)|February 13, 2013
Induced pluripotent stem cells with a mitochondrial DNA deletionAnne B C Cherry, Katelyn E Gagne, Erin M McLoughlin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial CarcinomaJonathan Rosenberg, Srikala S Sridhar, Jingsong Zhang, et al.Pageof 19